The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 66 results
March 2021
-
Media Release
Health Canada approves Kesimpta®, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis (RRMS)
Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing… -
Media Release
Novartis’ KISQALI® (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
KISQALI® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners…
June 2020
-
Media Release
Statement from Novartis on AVXS-101 filing with Health Canada
June 18, 2020 – Dorval - Novartis Pharmaceuticals Canada Inc. is pleased to announce the filing of a marketing application to Health Canada for AVXS-101 (onasemnogene abeparvovec), known in the US… -
Media Release
Long-term, relapse-free survival data for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery presented at ASCO20
More than half of patients with BRAF-mutated advanced melanoma treated with Tafinlar + Mekinist were alive and free of a relapse at five years1 Study conclusions drawn from the five-year follow-up…
